|Post IPO Valuation|
AEterna Zentaris Inc. is a drug development company specialized in oncology and endocrine therapy. The Companyâ€™s product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The priorities in oncology are its Phase III program with perifosine in multiple myeloma and its Phase II program in multiple cancers, including metastatic colon cancer, as well as Phase II program with AEZS-108 in advanced endometrial and advanced ovarian cancer combined with potential developments in other cancer indications. In endocrinology, the Companyâ€™s program is the reactivation of a Phase III trial with AEZS-130 (SolorelTM) as a growth hormone (GH) stimulation test for the diagnosis of GH deficiency in adults (AGHD).